Business Context and Reporting Period
Hyperliquid Strategies Inc (the "Company") filed a Form 8-K on December 2, 2025, reporting the completion of its business combination with Sonnet BioTherapeutics Holdings, Inc. ("Sonnet") and Rorschach I LLC ("Rorschach"). Following the closing, the Company's common stock began trading on the Nasdaq Capital Market under the symbol "PURR" on December 3, 2025. The transaction involved a series of mergers where Sonnet and Rorschach became direct wholly-owned subsidiaries of the Company.
Key Financial Metrics and Capital Structure
This filing is a Current Report and does not contain audited financial statements, revenue, profit, or cash flow data for the Company. Financial statements for the acquired business and pro forma information are scheduled to be filed within 71 days. The filing details the post-closing capital structure:
- Common Stock Outstanding: 127,025,563 shares.
- Series A Preferred Stock: 166,172.794 shares issued, convertible into an aggregate of 26,587,647 shares of Common Stock (subject to blocker provisions).
- Advisor Warrants: Three warrants issued to Rorschach Advisors LLC, exercisable for an aggregate of 27,394,800 shares of Common Stock at exercise prices of $9.375, $12.50, and $18.75.
- Legacy Warrants: Former Company Out-Of-The-Money Warrants converted, exercisable for up to 2,809,001 shares of Common Stock.
- Contingent Value Rights (CVRs): Issued to former Sonnet stockholders; payment is contingent upon the monetization of legacy assets within three years.
- Equity Incentive Plan: 6,351,278 shares reserved for the 2025 Equity Incentive Plan.
Material Changes and Corporate Actions
The filing documents significant structural and governance changes resulting from the business combination:
- Merger Consideration: Sonnet common stock was converted into one-fifth of one share of Common Stock and one CVR. Rorschach equityholders received shares based on the value of cash and HYPE Tokens held, divided by $1.25.
- Board Composition: The Board was reconstituted with seven new directors (Bob Diamond, Jeff Tuder, Eric S. Rosengren, Thomas C. King, Larry Leibowitz, Nailesh Bhatt, and Albert Dyrness). The Board size was subsequently increased to eight, with David Schamis re-appointed.
- Executive Officers: David Schamis (CEO), Brett Beldner (CFO), and Jeroen Nieuwkoop (COO) continued in their roles.
- Charter Amendments: The Company adopted a Restated Charter and Bylaws, including a classified board structure, restrictions on stockholder action without a meeting, and a new Code of Business Conduct and Ethics.
Material Agreements and Financing
- Advisor Agreements: Entered into an Advisor Rights Agreement and Strategic Advisor Agreement with Rorschach Advisors LLC. The Advisor is entitled to equity grants (5% of shares and 15% of warrants) if the Company raises equity financing during the five-year term.
- ChEF Purchase Agreement: Entered into an agreement with Chardan Capital Markets LLC allowing the Company to sell up to $1.0 billion of Common Stock over time. Proceeds are intended for general corporate purposes, including potential purchases of HYPE Tokens.
- Registration Rights: Entered into agreements providing customary registration rights for the Advisor and certain Rorschach investors.
Outlook, Risks, and Contingencies
Outlook and Strategy: The Company plans to utilize proceeds from the ChEF Purchase Agreement for general corporate purposes and potential HYPE Token acquisitions. The Strategic Advisor Agreement focuses on providing technical advisory services related to the digital asset ecosystem and Hyperliquid.
Risks and Contingencies:
- CVR Uncertainty: There is no assurance that holders of Contingent Value Rights will receive any payment, as it depends on the monetization of legacy assets within three years and the proceeds exceeding specific deductions and liabilities.
- Financing Discretion: Sales under the ChEF Purchase Agreement are at the Company's sole discretion and depend on market conditions and trading prices.
- Blocker Provisions: Conversion of Series A Preferred Stock is subject to beneficial ownership limitations (4.99% or 9.99% thresholds).
Key Facts for Investor Verification
- Verify the trading status and initial price of the new ticker symbol "PURR" on the Nasdaq Capital Market.
- Review the upcoming pro forma financial information (due within 71 days) to assess the combined entity's financial health, as current data is unavailable.
- Monitor the status of the Contingent Value Rights (CVRs) and the timeline for any potential monetization of Sonnet's legacy assets.
- Track the Company's utilization of the $1.0 billion ChEF Purchase Agreement and any subsequent purchases of HYPE Tokens.
- Confirm the vesting schedules and exercise prices of the Advisor Warrants and Series A Preferred Stock conversion terms.